Problem.
Demonstrating efficacy is challenging with CNS therapeutics.
Only
8%
Phase 1 to FDA approval
Less than
½
as likely as other therapeutic areas
And
2x
as likely to fail in phase 3
CNS diseases are often complex, poorly defined, and difficult to measure. Also, patients are known to exhibit highly differential responses to CNS therapeutics, highlighting the need for patient measurement and stratification.
Solution.
Objective and automated measurement using multimodal AI enhances signal detection.
Increased
power.
Deliberate helps clinical trial sponsors achieve enhanced endpoint reliability, reduced sample size, faster completion, and lower cost.
Comprehensive measurement.
Our platform captures and analyzes signs beyond what a human clinician can perceive, including accurate side effect quantification.
Precision enrollment & enrichment.
With Deliberate, sponsors can screen and verify patients, capture validated baseline measures, and even perform patient enrichment via a companion Dx.
How we do it.
Our multimodal AI platform analyzes biomarker constellations™ to objectively measure disease signs across CNS indications
Distinguished Poster Award
18th Annual Scientific Meeting, 2022
Benefits for sponsors.
Our multimodal AI platform analyzes biomarker constellations™ to objectively measure disease signs across CNS indications
Make your CNS clinical trial
more Deliberate.
Measurement beyond human perception
Enhanced signal detection
Biomarker Constellation analysis and AI-COAs
Precision enrollment, enrichment, and companion Dx
